EMA finds no link between GLP-1 drugs and suicidal thoughts, self-harm
EMA finds no link between GLP-1 drugs and suicidal thoughts, self-harm
EMA finds no link between GLP-1 drugs and suicidal thoughts, self-harm
Published: Apr 12, 2024
By Tristan Manalac
BioSpace
The European Medicines Agency announced on Friday that it has found no causal association between GLP-1 receptor agonists—a popular class of weight-loss treatments that include Novo Nordisk’s Wegovy (semaglutide)—and the risks of suicidal thoughts and actions.
The agency arrived at this conclusion following a review by its Pharmacovigilance Risk Assessment Committee (PRAC), which looked at several cases of suicidal thoughts and self-harm among patients taking semaglutide and liraglutide, which is also owned by Novo and is sold under the brand name Saxenda.
In addition to semaglutide, which is also marketed as Ozempic for type 2 diabetes, the PRAC looked at other GLP-1 medicines including Eli Lilly’s Trulicity (dulaglutide) and AstraZeneca’s Byetta (exenatide).
In its review, the committee also evaluated data from a recent study, published in January 2024 in Nature Medicine, which used electronic health record data from over 240,000 overweight or obese patients to establish that GLP-1 medications do not aggravate suicidal ideation. Instead, the study found that GLP-1 analogs were associated with a significantly lower likelihood of suicidal thoughts.
This finding was consistent with a separate analysis using electronic records of nearly 1.6 million type 2 diabetes patients.
The European Medicines Agency (EMA) also conducted its own study to look at the potential link between suicidal thoughts and self-harm with the use of GLP-1 treatments. Their data supported no causal link, according to the EMA’s Friday announcement.
With this conclusion, the PRAC has said that it will require no update on the product information of GLP-1 products. Still, companies holding marketing authorizations should “continue to monitor these events closely … as part of their pharmacovigilance activities.”
The EMA first looked into the suicide risks of GLP-1 medications in July 2023, spurred by the Icelandic Medicines Agency which flagged several reports of suicidal thoughts and self-harm in people taking Saxenda and Ozempic.
In December 2023, after a preliminary review, the PRAC announced that it could not draw a definitive conclusion about a causal link. Pointing to “several issues that still need to be clarified,” the committee asked for “further clarifications” from drugmakers regarding their GLP-1 products. Earlier this week, the EMA announced that the PRAC would convene to continue its review.
The FDA in January 2024 also initiated an investigation into the suicidal ideation and self-harm risks of GLP-1 analogs, but a week later in a preliminary review found no evidence to support such an association.
Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at [email protected] or [email protected].
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: